-Reuters
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition
William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair